Program
Wednesday, May 5
|
15:00-18.00
19:30 |
 |
Meeting for members of the association
Get-Together at Hyatt Regency Mainz |
Thursday, May 6
|
08:30-08:45
|
 |
Welcoming Address
Ch. Huber, Mainz |
|
||
| Workshop 1: "ANTIBODY THERAPY" Chairpersons: B. Dörken (Berlin), M. Gramatzki (Erlangen) |
||
|
||
|
08:45-09:00
|
|
Introduction by B. Dörken and M. Gramatzki
|
|
||
|
09:00-09:30
|
|
"Disrupting signaling pathways with anti-ErbB receptor antibodies: biological and clinical implications"
J. Albanell, Barcelona, Spain |
|
||
|
09:30-10:00
|
|
"Mechanisms of killing by anti-cancer antibodies'"
M. Glennie, Southhamptom, United Kingdom |
|
||
|
10:00-10:30
|
|
Coffee Break
|
|
||
|
10:30-10:45
|
|
"Bispecific costimulatory molecules for activation of tumor-killing lymphocytes"
R. Weth, Frankfurt/Main, Germany |
|
||
|
10:45-11:00
|
|
"Antibody-based immunoreceptors: the impact of signalling domain, binding affinity and costimulation"
H. Abken Cologne, Germany |
|
||
|
11:00-11:15
|
|
"Tolerability and efficacy of the trifunctional antibody removab® (anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study"
P. Wimberger, Essen, Germany |
|
||
|
11:15-11:30
|
|
"HLA DR-directed bispecific single-chain Fv antibodies for lymphoma therapy"
Y. Wachter, Erlangen, Germany |
|
||
|
11:30-11:45
|
|
NN
|
|
||
|
11:45-12:15
|
|
Round Table and Conclusion
|
|
||
|
12:15-12:55
|
|
Poster visits
|
|
||
|
12:55-13:45
|
|
Lunch
|
|
||
| Workshop 2: "IMMUNE ESCAPE MECHANISMS / NK CELL RECOGNITION" Chairpersons: A. Knuth (Zürich), B. Seliger (Halle) |
||
|
||
|
13:45-14:00
|
|
Introduction by A. Knuth and B. Seliger
|
|
||
|
14:00-14:30
|
|
"MHC antigens and tumor immune escape"
F. Garrido, Granada, Spain |
|
||
|
14:30-15:00
|
|
"Induction of protective T cell responses by activated NK cells"
R. Mocikat, Munich, Germany |
|
||
|
15:00-15:15
|
|
"Increased frequency of CTLA4+ TGFbeta+ CD4+ CD25+ T cells in peripheral blood of patients with chronic lymphatic leukemia and multiple myeloma"
M. Beyer, Cologne, Germany |
|
||
|
15:15-15:30
|
|
"MMP-7 inhibits CTL - tumor cell interaction"
S. Gregor, Mainz, Germany |
|
||
|
15:30-16:00
|
|
Coffee Break
|
|
||
|
16:00-16:15
|
|
"Genetically modified natural killer cells specifically recognizing the tumor-associated antigens ErbB2/HER2 and EpCAM"
C. Uherek, Frankfurt/Main, Germany |
|
||
|
16:15-16:30
|
|
"Rapid functional exhaustion and deletion of cytotoxic T lymphocytes following immunization with recombinant adenovirus"
E. Scandella, St. Gallen, Switzerland |
|
||
|
16:30-16:45
|
|
"High frequency of functionally active Melan-A specific T cells in a patient with progressive immunoproteasome-deficient melanoma"
A. Mackensen, Regensburg, Germany |
|
||
|
16:45-17:15
|
|
Round Table and Conclusion
|
|
||
|
17:15-17:45
|
|
Poster visits
|
|
||
| Special Lecture | ||
|
||
|
17:45-18:30
|
|
"Pitfalls and remedies in the exploitation of therapeutic T-cell immunity against cancer"
C.J.M. Melief, Leiden, Netherlands |
Friday, May 7
| Workshop 3: "ADOPTIVE T CELL TRANSFER" Chairpersons: A. Mackensen (Regensburg), M. Theobald (Mainz) |
||
|
||
|
08:30-08:45
|
|
Introduction by A. Mackensen and M. Theobald
|
|
||
|
08:45-09:15
|
|
"T Cell Transfer Therapy"
M. Dudley, Bethesda, USA |
|
||
|
09:15-09:45
|
|
"The Influence of T Cell Receptor Genes on Tumor Cell Recognition"
M. Nishimura, Chicago, USA |
|
||
|
09:45-10:15
|
|
Coffee Break
|
|
||
|
10:15-10:30
|
|
"Adoptive T cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma: a phase I clinical study"
A. Mackensen, Regensburg, Germany |
|
||
|
10:30-10:45
|
|
"Large Scale In Vitro Expansion of Polyclonal Human CD4+CD25high Regulatory T Cells"
P. Hoffmann, Regensburg, Germany |
|
||
|
10:45-11:00
|
|
"Reversible HLA multimers (streptamers) for isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens"
J. Neudorfer, Munich, Germany |
|
||
|
11:00-11:15
|
|
"Therapeutic efficacy of RAGE-1 and MAGE-9 peptide specific cytotoxic T cell clones in renal cell carcinoma"
N. Oehlrich, Heidelberg, Germany |
|
||
|
11:15-11:30
|
|
"The role of glycosylation as a modulator for signalling strength in T cells"
B. Hauptrock, Mainz, Germany |
|
||
|
11:30-12:00
|
|
Round Table and Conclusion
|
|
||
|
12:00-12:40
|
|
Poster Visits
|
|
||
|
12:40-13:30
|
|
Lunch
|
|
||
| Workshop 4: "THERAPEUTIC VACCINATION" Chairpersons: G. Schuler (Erlangen), T. Wölfel (Mainz) |
||
|
||
|
13:30-13:45
|
|
Introduction by G. Schuler and T. Wölfel
|
|
||
|
13:45-14:15
|
|
"Specific immunotherapy of cancer: Identification, functional and molecular characterization of tumor reactive cytolytic T lymphocytes"
P. Romero, Lausanne, Switzerland |
|
||
|
14:15-14:35
|
|
"DC Vaccination - where do we stand? Results of
a prospective randomized trial."
D. Schadendorf, Mannheim, Germany |
|
||
|
14:35-14:50
|
|
"Migration of Dendritic Cells regional lymph nodes in a vaccination trial"
A. Riccobon, Forlì, Italy |
|
||
|
14:50-15:05
|
|
"Transitory response to vaccination with PSCA-/PSA-Peptide loaded, autologous dendritic cells in patients with metastatic, hormon-refractory prostate cancer"
A.K. Kaskel, Freiburg, Germany |
|
||
|
15:05-15:25
|
|
Coffee Break
|
|
||
|
15:25-15:40
|
|
"Vaccination with WT1 induces high frequency memory and effector T cells in peripheral blood and bone marrow associated with complete remission of recurrent AML"
A. Letsch, Berlin, Germany |
|
||
|
15:40-15:55
|
|
"LUD00-014: Phase I Study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) in patients with NY-ESO-1 or LAGE positive cancers"
A. Bender, Frankfurt/Main, Germany |
|
||
|
15:55-16:10
|
|
"Tumor vaccination after allogeneic bone marrow cell reconstitution of the non-myeloablatively conditioned tumor-bearing murine host"
M. Zöller, Heidelberg, Germany |
|
||
|
16:10-16:40
|
|
Round Table and Conclusion
|
|
||
|
16:40-16:50
|
|
Final Remarks
H.-G. Rammensee |
Download
Program as PDF-file (88 KB)
